Form 4: DNA X CFO Crolius Granted 35,000 Restricted Stock Units

DNA X, Inc.'s Chief Financial Officer, Clayton Crolius, was granted 35,000 restricted stock units vesting over one year.

Summary

• Clayton Crolius, Chief Financial Officer of DNA X, Inc. (SONM), reported an acquisition of securities.
• On February 9, 2026, Crolius was granted 35,000 restricted stock units (RSUs).
• These RSUs vest in equal monthly installments over a one-year period, contingent on his continued service to the company.
• Each restricted stock unit represents the contingent right to receive one share of DNA X, Inc. common stock.
• Following this transaction, Crolius beneficially owns 36,719 securities, consisting of 1,719 shares of common stock and 35,000 unvested restricted stock units.
• The reported numbers reflect a 1-for-18 reverse stock split effected by DNA X, Inc. on October 27, 2025.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive event, reflecting standard executive compensation practices and an effort to align management incentives, without indicating significant operational changes or financial performance shifts.

Positives

• The grant of 35,000 restricted stock units to the Chief Financial Officer aligns management's interests with shareholder value.
• The vesting schedule over one year encourages long-term retention and performance from a key executive.

Risks

• The value of the restricted stock units is subject to the future performance and stock price of DNA X, Inc.
• The vesting of the RSUs is contingent on the CFO's continued service, posing a risk if his employment terminates before full vesting.

Future Outlook

The grant of restricted stock units with a one-year vesting schedule indicates an expectation of continued service from the Chief Financial Officer and a desire to incentivize long-term performance.

Industry Context

StockSavvy.ai notes that executive compensation, particularly through equity grants like RSUs, is a standard practice across industries to align management incentives with shareholder interests. The specific terms of the grant, such as vesting schedules, are often tailored to company-specific retention and performance goals.

Comparison to Industry Standards

• Equity grants to C-suite executives, such as CFOs, are a common component of compensation packages in publicly traded companies, comparable to practices at biotech and technology firms like Illumina or Qualcomm, which frequently use RSUs to attract and retain talent.
• The one-year monthly vesting schedule is a relatively short-term vesting period compared to typical multi-year (e.g., 3-4 year) vesting schedules often seen for initial grants or larger equity awards at established companies, which might suggest a specific retention focus or a smaller, more frequent grant strategy.

Related Party Transactions

• The grant of restricted stock units to the Chief Financial Officer is a related party transaction, as it involves compensation to an executive.

Stakeholder Impact

• Shareholders: The grant of RSUs dilutes existing shareholder value slightly upon vesting but aims to incentivize the CFO to enhance long-term shareholder value.
• Employees: This transaction is specific to a key executive and does not directly impact the broader employee base, though it reflects the company's executive compensation strategy.

Next Steps

• Continued vesting of the 35,000 restricted stock units over the next year, subject to Clayton Crolius's continued service.
• Future Form 4 filings will be required for any subsequent transactions by Clayton Crolius.

Key Dates

Recommendation

This Form 4 filing details a routine grant of restricted stock units to a key executive, which is a standard component of executive compensation. It does not provide information on the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Therefore, a "hold" recommendation is appropriate as this filing alone does not present new information to alter an existing investment thesis.

Keywords

DNA X Inc., SONM, Clayton Crolius, CFO, Restricted Stock Units, RSU Grant, Insider Transaction, Form 4, Executive Compensation, Stock Split